Abstract 790P
Background
Endometrial carcinoma (EC) guidelines (NCCN, ESGO) suggest molecular analysis (MA) for incorporation into risk criteria. Prognostic value of TCGA-based classification has been validated, but adoption into adjuvant treatment decisions is still under evaluation. Examples of real-world upfront MA analysis in EC are scarce. We aim to evaluate our routine implementation of Next Generation Sequencing (NGS) of EC patients.
Methods
In November 2020, we implemented routine immunohistochemistry (IHC) (p53, MMR) & NGS for TCGA-based prognostication of all EC primary resections at a single institution. NGS was a 69 gene panel including POLE, TP53, PTEN, CTNNB1, KRAS, ERBB2, & PIK3CA. A questionnaire directed to treating oncologists evaluating impact of MA on adjuvant management decisions and counselling was utilized.
Results
189 patients amongst 7 treating gynecologic oncologists were evaluated over the initial 13 months. Primary stage of disease was; I: 139 (73.5%), II: 11(5.8%), III: 27 (14.3%), IV: 12 (6.4%). Prognostic classifiers were: POLE: 10 (5.3%); MMRd 52 (27.5%); NSMP: 86 (45.5%); and p53: 41 (21.7%), including multiple-classifiers: 10 (5.3%) MMRd-p53 and 4 (2.1%) POLE-p53. The classifiers with the most impact for providers were MMRd: 27 (14.3%) and p53: 22 (11.6%). Prognostic classification impacted patient counselling in 72 (38.1%) of patients (POLE 66.7%; MMRd 59.5%; p53 52.5%; NSMP 12.6%; p<0.001), with NSMP having the least impact. MA impacted treatment recommendations in 19 (10%) of patients. MA altered treatment recommendations compared to recommendations by histological properties in 8 (4.2%) patients. MA significantly impacted treatment recommendations with increasing stage (I: 5.8%, II: 9.1%, III: 22.2%, IV: 33.3%, p=0.002). MA significantly altered treatment recommendations deviating from histological recommendations with increasing stage (I: 1.4%, II: n/a, III: 14.8%, IV: 16.7%, p=0.002).
Conclusions
Comprehensive uniform molecular analysis of endometrial carcinoma via combined IHC and NGS upon primary resection is feasible and contributes to patient counseling and treatment recommendations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The University of Colorado.
Funding
Has not received any funding.
Disclosure
B.R. Corr: Financial Interests, Institutional, Advisory Board: GSK, Gilead, Immunogen, Zentalis, Merck; Financial Interests, Institutional, Funding: Clovis, Immunogen. C. Walsh: Financial Interests, Institutional, Advisory Board: Immunogen, Regeneron. L. Brubaker: Financial Interests, Institutional, Advisory Board: AstraZeneca. S.R. Guntupalli: Financial Interests, Institutional, Advisory Board: Seagen. D. Aisner: Financial Interests, Institutional, Funding: Takeda, Loxo Oncology, Eli Lily, Sanofi Genzyme, AstraZeneca, Genentech, AbbVie, Janssen. All other authors have declared no conflicts of interest.
Resources from the same session
628P - Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers
Presenter: Amos Stemmer
Session: Poster session 11
629P - First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
Presenter: David Tougeron
Session: Poster session 11
630P - Determining a prognostic score using imaging to assess the benefit of combo anti-PD1 + anti-CTL4 vs anti-PD1 in patients with metastatic MSI/dMMR colorectal cancer (mCRC MSI)
Presenter: Remy Barbe
Session: Poster session 11
631P - Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy
Presenter: Giulia Maddalena
Session: Poster session 11
632P - Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
Presenter: Sebastian Meltzer
Session: Poster session 11
633P - Genomic alterations in SPEN predict outcome of immune checkpoint therapy in gastrointestinal cancer
Presenter: Changxiong Wu
Session: Poster session 11
634P - The ave-rec phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable ESMO high risk rectal cancers
Presenter: Michael Michael
Session: Poster session 11
635P - Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
Presenter: Marc van den Eynde
Session: Poster session 11